Karyopharm Therapeutics
KPTI
88 hedge funds and large institutions have $415M invested in Karyopharm Therapeutics in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 21 reducing their positions, and 14 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 21
39% more capital invested
Capital invested by funds: $298M → $415M (+$117M)
0.23% less ownership
Funds ownership: 4.38% → 4.15% (-0.23%)
2% less call options, than puts
Call options by funds: $2.65M | Put options by funds: $2.7M
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2% less funds holding
Funds holding: 90 → 88 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$7.45M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.31M |
| 5 |
DAM
Doheny Asset Management
Los Angeles,
California
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$17.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.6M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.43M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
-$2.33M |
KPTI Hedge Fund Activity: Q1 2018 in Review
88 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2018, worth a combined $415M — up 39% from $298M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KPTI and 13 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 39 added.
The largest buyer was Millennium Management, adding an estimated $11.1M. The largest seller was Point72 Asset Management, cutting an estimated $18.5M.
- 88 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2018, down from 90 in Q4 2017.
- Funds reported $415M of Karyopharm Therapeutics stock for Q1 2018, up 39% quarter-over-quarter.
- 13 funds opened new Karyopharm Therapeutics positions in Q1 2018 and 14 closed out, a net change of -1 holder.
- The largest Karyopharm Therapeutics buyer in Q1 2018 was Millennium Management, an estimated $11.1M added.
- The largest Karyopharm Therapeutics seller in Q1 2018 was Point72 Asset Management, an estimated $18.5M sold.
Based on aggregated 13F filings for Q1 2018.